Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

Rhea-AI Summary

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) announced its participation in two investor conferences on May 24, 2022. The company will host a fireside chat at the H.C. Wainwright Global Life Sciences Conference at 7:00 AM ET, followed by another at the UBS Global Healthcare Conference at 8:30 AM ET. Both presentations will be available via webcast and archived for later replay on the Madrigal website. The company focuses on developing novel therapeutics for non-alcoholic steatohepatitis (NASH), with its lead candidate resmetirom under evaluation in Phase 3 studies.

CONSHOHOCKEN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), announced today its management team will participate in two upcoming investor conferences:

H.C. Wainwright Global Life Sciences Conference
Fireside chat at 7:00 AM ET on Tuesday, May 24, 2022.

UBS Global Healthcare Conference
Fireside chat at 8:30 AM ET on Tuesday, May 24, 2022.

The presentations will be webcast and archived recordings will be available for replay in the Investors & Media section of the Madrigal website after the events.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

When will Madrigal Pharmaceuticals participate in investor conferences?

Madrigal Pharmaceuticals will participate in investor conferences on May 24, 2022.

What is the schedule for Madrigal Pharmaceuticals' fireside chats?

The first fireside chat is at 7:00 AM ET at the H.C. Wainwright Global Life Sciences Conference, followed by another at 8:30 AM ET at the UBS Global Healthcare Conference.

Where can I watch the Madrigal Pharmaceuticals conference presentations?

The presentations will be webcast and archived on Madrigal's website in the Investors & Media section.

What does Madrigal Pharmaceuticals focus on?

Madrigal Pharmaceuticals is focused on developing therapeutics for non-alcoholic steatohepatitis (NASH).

What is Madrigal Pharmaceuticals' lead candidate for NASH?

The lead candidate is resmetirom, designed to target key causes of NASH.